NAD+ Peptide (1000MG)

This groundbreaking study investigated whether long-term supplementation with nicotinamide mononucleotide (NMN), a key NAD+ precursor, could restore NAD+ levels in aged mice and reverse age-associated physiological decline. Led by researchers Yoshino, Mills, and colleagues at Washington University School of Medicine, the study examined the effects of chronic NMN administration on metabolic function, gene expression, mitochondrial health, and tissue physiology. Over a 12-month period, aged mice received daily NMN supplementation at doses ranging from 100-300 mg/kg through drinking water. Results demonstrated that NMN successfully restored NAD+ to more youthful levels, improved metabolic parameters, enhanced physical performance, and prevented age-related gene expression changes across multiple organ systems.

NAD+ is a critical molecule that supports essential cellular processes including energy production, DNA repair, and stress resistance. Research demonstrates that NAD+ levels decline significantly with age across multiple tissues including liver, muscle, adipose tissue, and brain. This decline impairs mitochondrial function, disrupts metabolic signaling, and increases vulnerability to age-related diseases. NMN serves as a direct NAD+ precursor that can be rapidly absorbed and converted into NAD+ within cells. Unlike other NAD+ boosting strategies, NMN provides an efficient pathway to replenish cellular NAD+ pools through the salvage pathway, making it a promising intervention for counteracting age-related metabolic dysfunction and restoring cellular health.

The study compared young (5-month-old) and aged (22-month-old) C57BL/6 mice over a 12-month treatment period. NMN was administered daily at doses of 100-300 mg/kg through drinking water, with a separate oral gavage experiment confirming rapid absorption and conversion of NMN into NAD+ within minutes. Comprehensive assessments included body weight and food intake monitoring, physical activity and energy expenditure measurements, insulin sensitivity testing through glucose and insulin tolerance tests, lipid metabolism and inflammation markers, mitochondrial function via respiration assays, and extensive gene expression profiling across liver, adipose tissue, and skeletal muscle. These multifaceted evaluations enabled researchers to comprehensively assess NMN's effects as an NAD+ precursor across metabolic and physiological systems.

Within minutes of administration, NMN was efficiently converted to NAD+ in liver and muscle tissues, as confirmed by isotopic tracing studies. Aged mice receiving NMN experienced restoration of NAD+ levels comparable to those observed in younger animals, representing a remarkable reversal of age-related NAD+ decline. This restoration corresponded with increased activity of NAD-dependent enzymes, particularly SIRT1, a key regulator of metabolism and longevity. NMN supplementation also stimulated mitochondrial regulators such as PGC-1α, enhancing mitochondrial biogenesis and metabolic turnover. Aged mice displayed elevated oxygen consumption, improved respiratory quotient, and sustained energy expenditure relative to age-matched control animals, demonstrating functional metabolic rejuvenation.

NMN-treated mice exhibited broad improvements consistent with restored metabolic health across multiple organ systems:

• Enhanced metabolic rate: Increased whole-body oxygen consumption (VO₂) and energy expenditure during aging, indicating improved metabolic efficiency
• Superior insulin sensitivity: Lower glucose levels during insulin tolerance tests and reduced hepatic triglyceride accumulation, suggesting improved glucose metabolism
• Better visual function: Reduced retinal degeneration and stronger electroretinography responses, demonstrating neuroprotective effects
• Reduced inflammation: Gene pathway analysis revealed suppression of cytokine and immune activation pathways in white adipose tissue
• Improved mitochondrial function: Skeletal muscle displayed higher maximal respiratory capacity and restored mitochondrial oxidative function

Overall, NMN promoted multi-system improvements linked to mitochondrial and metabolic rejuvenation, suggesting comprehensive anti-aging effects.

NMN is efficiently converted into NAD+ via the cellular salvage pathway, bypassing rate-limiting steps that become compromised with aging. Gene expression analysis revealed that NMN prevented 76% of age-related gene expression changes in skeletal muscle and 73% in adipose tissue, demonstrating profound effects on age-related transcriptional drift. Elevated NAD+ levels activated SIRT1-dependent signaling cascades, leading to improved mitochondrial oxidative phosphorylation, enhanced cellular energy production, and suppression of age-associated inflammatory gene signatures. The molecular data collectively demonstrate that NMN's role as an NAD+ precursor re-establishes youthful transcriptional and metabolic profiles across multiple tissue types, addressing fundamental mechanisms of aging at the cellular level.

Throughout the 12-month supplementation period, NMN demonstrated an excellent safety profile with no adverse effects observed. Comprehensive toxicological assessments including hematology panels and histopathological examinations revealed no abnormalities. Organ histology remained normal across liver, kidney, and heart tissues, with no pathological changes detected. Importantly, NMN treatment did not increase mortality rates or cause behavioral abnormalities. Food intake remained stable and normal throughout the study period. These findings confirm the long-term tolerability of NMN supplementation and support its potential for safe use in translational contexts and future human trials.

This study strengthens the hypothesis that declining NAD+ levels represent a central driver of age-related metabolic dysfunction and physiological decline. By restoring NAD+ through NMN supplementation, researchers demonstrated multi-system rejuvenation encompassing metabolism, visual function, mitochondrial capacity, inflammation reduction, and enhanced physical activity. The comprehensive nature of these improvements highlights NMN's therapeutic potential as an intervention that addresses multiple aspects of aging simultaneously rather than targeting individual pathways. As NAD+ research accelerates globally, these robust preclinical findings provide a strong foundation for human clinical trials aimed at targeting age-associated decline through NAD+ precursor interventions. The results suggest that maintaining optimal NAD+ levels may be crucial for healthy aging and metabolic resilience.

NMN, a potent NAD+ precursor, substantially counteracted age-associated physiological decline in mice through restoration of NAD+ levels, enhanced mitochondrial function, stabilized metabolic regulation, and suppressed inflammatory gene signatures. The 12-month study validated the therapeutic direction of ongoing NAD+ research focused on combating metabolic aging and age-related dysfunction. These findings demonstrate that NMN supplementation can reverse multiple hallmarks of aging at the molecular, cellular, and physiological levels. Future research will determine the translational impact of NMN on human aging, metabolic health, and clinical outcomes, with promising implications for extending healthspan and combating age-related diseases.